Prof. Stephanie Federico, Margherita Persico, Letizia Trevisan, Chiara Biasinutto, Dr. Giovanni Bolcato, Dr. Veronica Salmaso, Prof. Tatiana Da Ros, Dr. Teresa Gianferrara, Dr. Filippo Prencipe, Sonja Kachler, Prof. Karl-Norbert Klotz, Prof. Sabrina Pacor, Prof. Stefano Moro, Prof. Giampiero Spalluto
{"title":"[1,2,4]三唑[1,5-c]嘧啶类化合物在肿瘤细胞A3腺苷受体研究中的应用","authors":"Prof. Stephanie Federico, Margherita Persico, Letizia Trevisan, Chiara Biasinutto, Dr. Giovanni Bolcato, Dr. Veronica Salmaso, Prof. Tatiana Da Ros, Dr. Teresa Gianferrara, Dr. Filippo Prencipe, Sonja Kachler, Prof. Karl-Norbert Klotz, Prof. Sabrina Pacor, Prof. Stefano Moro, Prof. Giampiero Spalluto","doi":"10.1002/cmdc.202300299","DOIUrl":null,"url":null,"abstract":"<p>The A<sub>3</sub> adenosine receptor is an interesting target whose role in cancer is controversial. In this work, a structural investigation at the 2-position of the [1,2,4]triazolo[1,5-<i>c</i>]pyrimidine nucleus was performed, finding new potent and selective A<sub>3</sub> adenosine receptor antagonists such as the ethyl 2-(4-methoxyphenyl)-5-(methylamino)-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidine-8-carboxylate (<b>20</b>, DZ123) that showed a K<sub>i</sub> value of 0.47 nM and an exceptional selectivity profile over the other adenosine receptor subtypes. Computational studies were performed to rationalize the affinity and the selectivity profile of the tested compounds at the A<sub>3</sub> adenosine receptor and the A<sub>1</sub> and A<sub>2A</sub> adenosine receptors. Compound <b>20</b> was tested on both A<sub>3</sub> adenosine receptor positive cell lines (CHO-A<sub>3</sub>AR transfected, THP1 and HCT16) and on A<sub>3</sub> negative cancer cell lines, showing no effect in the latter and a pro-proliferative effect at a low concentration in the former. These interesting results pave the way to further investigation on both the mechanism involved and potential therapeutic applications.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"18 21","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines\",\"authors\":\"Prof. Stephanie Federico, Margherita Persico, Letizia Trevisan, Chiara Biasinutto, Dr. Giovanni Bolcato, Dr. Veronica Salmaso, Prof. Tatiana Da Ros, Dr. Teresa Gianferrara, Dr. Filippo Prencipe, Sonja Kachler, Prof. Karl-Norbert Klotz, Prof. Sabrina Pacor, Prof. Stefano Moro, Prof. Giampiero Spalluto\",\"doi\":\"10.1002/cmdc.202300299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The A<sub>3</sub> adenosine receptor is an interesting target whose role in cancer is controversial. In this work, a structural investigation at the 2-position of the [1,2,4]triazolo[1,5-<i>c</i>]pyrimidine nucleus was performed, finding new potent and selective A<sub>3</sub> adenosine receptor antagonists such as the ethyl 2-(4-methoxyphenyl)-5-(methylamino)-[1,2,4]triazolo[1,5-<i>c</i>]pyrimidine-8-carboxylate (<b>20</b>, DZ123) that showed a K<sub>i</sub> value of 0.47 nM and an exceptional selectivity profile over the other adenosine receptor subtypes. Computational studies were performed to rationalize the affinity and the selectivity profile of the tested compounds at the A<sub>3</sub> adenosine receptor and the A<sub>1</sub> and A<sub>2A</sub> adenosine receptors. Compound <b>20</b> was tested on both A<sub>3</sub> adenosine receptor positive cell lines (CHO-A<sub>3</sub>AR transfected, THP1 and HCT16) and on A<sub>3</sub> negative cancer cell lines, showing no effect in the latter and a pro-proliferative effect at a low concentration in the former. These interesting results pave the way to further investigation on both the mechanism involved and potential therapeutic applications.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\"18 21\",\"pages\":\"\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2023-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202300299\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202300299","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines
The A3 adenosine receptor is an interesting target whose role in cancer is controversial. In this work, a structural investigation at the 2-position of the [1,2,4]triazolo[1,5-c]pyrimidine nucleus was performed, finding new potent and selective A3 adenosine receptor antagonists such as the ethyl 2-(4-methoxyphenyl)-5-(methylamino)-[1,2,4]triazolo[1,5-c]pyrimidine-8-carboxylate (20, DZ123) that showed a Ki value of 0.47 nM and an exceptional selectivity profile over the other adenosine receptor subtypes. Computational studies were performed to rationalize the affinity and the selectivity profile of the tested compounds at the A3 adenosine receptor and the A1 and A2A adenosine receptors. Compound 20 was tested on both A3 adenosine receptor positive cell lines (CHO-A3AR transfected, THP1 and HCT16) and on A3 negative cancer cell lines, showing no effect in the latter and a pro-proliferative effect at a low concentration in the former. These interesting results pave the way to further investigation on both the mechanism involved and potential therapeutic applications.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.